What is the price of ISRG in 2027?
Long-term equity research projections and market price forecasts for Intuitive Surgical, Inc. (ISRG) looking toward the year 2027 depend heavily on global adoption rates of its da Vinci surgical systems, recurring procedure volume growth, technological advancements in robotic-assisted surgery, and macroeconomic conditions. Financial analysts continuously revise long-term valuation targets based on corporate earnings growth and operational margin expansions across global healthcare markets.
Related FAQs
Executive compensation for the chief executive leadership directing Investec Group (an international specialized banking and wealth management enterprise operating primarily in South Africa and the United Kingdom) reflects financial services benchmar...
Building a high-quality equity portfolio involves selecting premier corporations that combine consistent earnings growth, strong competitive moats, and leadership in vital global industries.
Equity research brokerages evaluating Intuitive Surgical frequently note that its shares trade at high price-to-earnings valuation multiples compared to traditional healthcare equipment peers.
Wall Street equity analysts covering Intuitive Surgical predominantly assign consensus buy recommendations, supported by strong institutional sentiment and optimistic 12-month price targets.
Intuitive Surgical has faced extensive product liability lawsuits and safety scrutiny concerning its da Vinci surgical robotic systems.
Intuitive Surgical, Inc. (ISRG) operates as the pioneer and dominant global leader in robotic-assisted surgical systems, anchored by its flagship da Vinci platform.
FANUC Corporation of Japan is widely recognized as the world's largest pure-play industrial robotics and factory automation enterprise by installed base and revenue scale.
Intuitive Surgical (ISRG) equity shares trade at valuations heavily supported by its dominance in robotic-assisted surgical systems.
Taiwan Semiconductor Manufacturing Company (TSM) exhibits robust long-term upside potential, with Wall Street analyst consensus price targets averaging around $537 per share and high-end bull case forecasts reaching up to $700.
Public scrutiny and negative financial or regulatory news concerning Intuitive Surgical—the pioneer behind the Da Vinci surgical system—typically center around occasional product recalls, patient injury lawsuits related to surgical complications, or ...
Intuitive Surgical has been the target of extensive product liability lawsuits, personal injury claims, and wrongful death litigation concerning its flagship da Vinci robotic surgical system.
Equity research analysts covering MeiraGTx Holdings (trading under the ticker MGTX) overwhelmingly evaluate the stock with a consensus buy or strong buy rating.
Financial market analysts tracking Intuitive Surgical under the ticker ISRG widely view it as an exceptional long-term stock, driven by its dominant market share in robotic-assisted surgery systems like the da Vinci platform.